MetLife Investment Advisors LLC Buys 10,141 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

MetLife Investment Advisors LLC grew its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 38.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 36,638 shares of the medical research company’s stock after purchasing an additional 10,141 shares during the quarter. MetLife Investment Advisors LLC’s holdings in NeoGenomics were worth $750,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Suntrust Banks Inc. grew its holdings in NeoGenomics by 2.6% in the 4th quarter. Suntrust Banks Inc. now owns 39,959 shares of the medical research company’s stock worth $504,000 after buying an additional 1,028 shares in the last quarter. Legal & General Group Plc grew its holdings in NeoGenomics by 13.3% in the 4th quarter. Legal & General Group Plc now owns 11,964 shares of the medical research company’s stock worth $151,000 after buying an additional 1,405 shares in the last quarter. Citigroup Inc. grew its holdings in NeoGenomics by 9.0% in the 4th quarter. Citigroup Inc. now owns 26,490 shares of the medical research company’s stock worth $334,000 after buying an additional 2,180 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in NeoGenomics by 0.7% during the 1st quarter. Parametric Portfolio Associates LLC now owns 401,857 shares of the medical research company’s stock valued at $8,222,000 after purchasing an additional 2,834 shares in the last quarter. Finally, Great West Life Assurance Co. Can boosted its stake in NeoGenomics by 53.9% during the 4th quarter. Great West Life Assurance Co. Can now owns 9,851 shares of the medical research company’s stock valued at $120,000 after purchasing an additional 3,451 shares in the last quarter. Institutional investors and hedge funds own 84.10% of the company’s stock.

A number of brokerages have issued reports on NEO. Zacks Investment Research lowered GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target (down from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. Finally, BidaskClub downgraded Weyco Group from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 13th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $21.11.

Shares of NASDAQ NEO traded down $0.38 during mid-day trading on Thursday, reaching $23.52. The company had a trading volume of 740,158 shares, compared to its average volume of 1,098,805. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.46. The firm has a market capitalization of $2.28 billion, a PE ratio of 180.92 and a beta of 0.78. NeoGenomics, Inc. has a twelve month low of $11.05 and a twelve month high of $24.84. The stock has a 50 day simple moving average of $22.76.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, April 30th. The medical research company reported $0.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.03. The firm had revenue of $95.60 million for the quarter, compared to the consensus estimate of $89.71 million. NeoGenomics had a negative net margin of 0.14% and a positive return on equity of 3.07%. The business’s quarterly revenue was up 50.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.04 earnings per share. Sell-side analysts forecast that NeoGenomics, Inc. will post 0.18 EPS for the current fiscal year.

In related news, VP Jennifer Balliet sold 30,000 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $22.74, for a total value of $682,200.00. Following the completion of the sale, the vice president now owns 39,529 shares in the company, valued at $898,889.46. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider George Cardoza sold 151,676 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $22.82, for a total transaction of $3,461,246.32. Following the transaction, the insider now owns 452,507 shares of the company’s stock, valued at approximately $10,326,209.74. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 338,876 shares of company stock worth $7,674,362. 8.80% of the stock is currently owned by company insiders.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

See Also: What is a Fibonacci Channel?

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.